Addiction & Substance Use

Cognition Therapeutics advances zervimesine phase 2 trial, exploring its potential to slow cognitive decline in Alzheimer disease patients.

Achieve Life Sciences gains FDA acceptance for cytisinicline, a promising new drug for smoking cessation, showing significant abstinence rates in trials.

Altimmune's pemvidutide gains FDA Fast Track designation for alcohol use disorder.

AI chatbots pose significant mental health risks, often exacerbating issues like suicide, self-harm, and delusions, highlighting urgent regulatory needs.

The FDA has granted a Type C Meeting to Nutriband for their Aversa fentanyl patch, which aims to revolutionize pain management with its innovative abuse-deterrent technology.

Adial Pharmaceuticals just wrapped a successful end of phase 2 meeting with the FDA and will now advance its innovative treatment for alcohol use disorder, AD04.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

According to this pioneer, mental health professionals should embrace a new mindset: to consider how to can apply expertise not only within the confines of the exam room, but in boardrooms, in startups, in classrooms, and in community centers.

Brigitte Robertson, MD, shares information on innovative, genetically targeted treatments for alcohol use disorder, aiming to personalize care and improve patient outcomes.

Adial Pharmaceuticals advances its treatment for alcohol use disorder, AD04, with FDA meetings and promising genetic insights for targeted therapy.

A retired psychiatrist has a conversation with AI about substance use disorder treatment.

Female offenders in the criminal justice system are more likely to have experienced trauma and are more likely to be diagnosed with conditions such as PTSD and depression compared with male offenders.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

Given that individual differences exist regarding the effects of brain injury and gaps persist in the treatment continuum, challenges arise in treating individuals with acquired brain injury. Addressing these challenges can improve patient outcomes.

Through cinematherapy, Ted Perkins created a program centered on addiction in film that is now used in recovery centers and clinics across the US and Canada.

March 17 through March 23 is National Drug and Alcohol Facts Week 2025.

BLP-003, currently being evaluated for treatment-resistant depression and alcohol use disorder, today announced their global phase 2b clinical trial has completed patient enrollment.

The FDA gave positive feedback to Adial Pharmaceuticals regarding its proposed in vitro bridging strategy for the phase 3 formulation of AD04.

Why are older patients turning to cannabis for symptom relief?

The FDA has authorized key modifications to the administration protocol for injectable long-acting opioid use disorder treatment buprenorphine.

A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.

At the beginning of this year, US Surgeon General Vivek H. Murthy, MD, MBA, issued a health advisory warning about the link between alcohol use and the risk of cancer. Learn more about its implications for psychiatry here.

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

New positive results of a pharmacokinetics study of AD04 for alcohol use disorder confirms the near micro-dosing regimen planned for upcoming trials.

Check out new positive topline results from the open-label phase 2A study of BPL-003 in participants with moderate-to-severe alcohol use disorder.